Profile
| Metric | Value |
|---|---|
| Full Name | Cogent Biosciences, Inc. |
| Ticker | NASDAQ: COGT |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | cogentbio.com |
| Employees | 205 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $36.27 | |
| Price, 1D Change | +4.28% | |
| Market Cap | $6B | |
| - | ||
| PE Ratio | - | |
| Beta | 1.96 | |
| Revenue | $0 | |
| Revenue, 1Y Change | 0.00% | |
| EPS | -$2.46 | |
| EPS, 1Y Change | -2.00% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 1:4 | |
| Next Split | N/A | N/A |
| Last Ticker Change | UMRX | |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$2.46 | |
| EPS Estimate | -$2.25 | |
| EPS Est. Change | +8.79% | |
| Revenue | $0.00 | |
| Revenue Estimate | - | |
| Revenue Est. Change | - | |
| Current Price | $36.27 | |
| Price Target | - | $50.00 |
| Price Tgt. Change | - | +37.85% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$2.31 | -$2.42 | -4.56% | |
| -$2.40 | -$2.46 | -2.56% | |
| -$2.25 | N/A | +8.79% | |
| -$1.73 | N/A | +29.82% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| - | $0.00 | - | |
| - | $0.00 | - | |
| - | N/A | - | |
| $41.86M | N/A | - |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +339.64% | |
| Price, 3Y | +190.16% | |
| Market Cap, 1Y | +510.95% | |
| Market Cap, 3Y | +537.27% | |
| Revenue, 1Y | 0.00% | |
| Revenue, 3Y | 0.00% | |
| EPS, 1Y | -2.00% | |
| EPS, 3Y | -32.03% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $36.27 | |
| SMA 200 | $15.40 | |
| SMA 200 vs Price | -57.53% | |
| SMA 50 | $33.15 | |
| SMA 50 vs Price | -8.61% | |
| Beta | 1.96 | |
| ATR | $2.00 | |
| 14-Day RSI | 49.31 | |
| 10-Day Volatility | 41.21% | |
| 1-Year Volatility | 137.92% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $0.00 | |
| EPS | -$2.46 | |
| Gross Profit | -$4.40M | |
| Gross Margin | - | |
| Operating Profit | -$275.94M | |
| Operating Margin | - | |
| Net Income | -$255.86M | |
| Net Margin | - | |
| EBITDA | -$271.59M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.07 | |
| Current Ratio | 5.32 | |
| Quick Ratio | 5.32 | |
| - | ||
| F-Score | - | |
| Altman Z-Score | 41.08 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | - | |
| PB Ratio | 28.62 | |
| EV/EBITDA | -17.28 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $145.69M | |
| Cash & Equivalents | $287.08M | |
| Total Assets | $327.90M | |
| Current Assets | $296.47M | |
| Total Liabilities | $71.61M | |
| Current Liabilities | $55.71M | |
| Total Debt | $17.47M | |
| Short Term Debt | $1.57M | |
| Accounts Payable | $12.01M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $275.94M | |
| Operating Expenses | $275.94M | |
| Cost Of Goods Sold | $4.40M | |
| SG&A | $43.28M | |
| D&A | $4.35M | |
| Interest Expense | $0.00 | |
| Income Tax | $0.00 |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$207.79M | |
| CFI | $38.28M | |
| CFF | $214.45M | |
| Capex | $573.00K | |
| Free Cash Flow | -$208.36M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| JP Morgan | → | |
| Needham | → | |
| HC Wainwright & Co. | → | |
| Baird | → | |
| Leerink Partners | → | |
| HC Wainwright & Co. | → | |
| JP Morgan | → | |
| Stifel | ||
| Raymond James | ||
| Guggenheim | → |
Analyst sentiment
Institutional ownership
Screeners with COGT
Data Sources & References
- COGT Official Website www.cogentbio.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1622229/000119312525272334/0001193125-25-272334-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1622229/000095017025026115/0000950170-25-026115-index.htm
- COGT Profile on Yahoo Finance finance.yahoo.com/quote/COGT
- COGT Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/cogt
FAQ
What is the ticker symbol for Cogent Biosciences, Inc.?
The ticker symbol for Cogent Biosciences, Inc. is NASDAQ:COGT
Does Cogent Biosciences, Inc. pay dividends?
No, Cogent Biosciences, Inc. does not pay dividends
What sector is Cogent Biosciences, Inc. in?
Cogent Biosciences, Inc. is in the Healthcare sector
What industry is Cogent Biosciences, Inc. in?
Cogent Biosciences, Inc. is in the Biotechnology industry
What country is Cogent Biosciences, Inc. based in?
Cogent Biosciences, Inc. is headquartered in United States
When did Cogent Biosciences, Inc. go public?
Cogent Biosciences, Inc. initial public offering (IPO) was on March 29, 2018
Is Cogent Biosciences, Inc. in the S&P 500?
No, Cogent Biosciences, Inc. is not included in the S&P 500 index
Is Cogent Biosciences, Inc. in the NASDAQ 100?
No, Cogent Biosciences, Inc. is not included in the NASDAQ 100 index
Is Cogent Biosciences, Inc. in the Dow Jones?
No, Cogent Biosciences, Inc. is not included in the Dow Jones index
When was Cogent Biosciences, Inc. last earnings report?
Cogent Biosciences, Inc.'s most recent earnings report was on November 3, 2025
When does Cogent Biosciences, Inc. report earnings?
The next expected earnings date for Cogent Biosciences, Inc. is February 24, 2026